Unibest

Pharmaceutical intermediates

Dasatinib Hydrate Intermediates

2 pharmaceutical intermediates for Dasatinib Hydrate. Indication: Acute lymphoblastic leukemia; Chronic myeloid leukemia.

提交项目All intermediates

About Dasatinib Hydrate

Originator
Bristol Myers Squibb
Indication
Acute lymphoblastic leukemia; Chronic myeloid leukemia
Approved Date
06/28/2006
DS/DP
02/04/2025

Available intermediates

2 intermediates currently listed for Dasatinib Hydrate. Request specifications, documentation or a quotation for any item below.

Dasatinib Hydrate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(E)-N-(2-Chloro-6-methylphenyl)-3-ethoxyacrylamide863127-76-8//
2-Amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide302964-24-5//

Other programs under D

Dabigatran EtexilateDabigatran etexilate mesylateDabrafenib MesylateDacomitinibDanicopanDapagliflozinDaridorexant HydrochlorideDarolutamide

Building toward Dasatinib Hydrate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →